¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Tyrosine S Injection Treatment Course F"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • rescue treatment
    ±¸Á¶Ã³Ä¡
  • self-treatment
    ÀÚ°¡Ä¡·á
  • salvage treatment
    ±¸Á¦Ä¡·á
  • self-administered treatment
    ÀÚ±âÅõ¾àÄ¡·á
  • sewage treatment
    Çϼöó¸®
  • shock treatment
    Ãæ°ÝÄ¡·á
  • sludge treatment
    ½½·¯Áöó¸®
  • smoke treatment
    ¸Å¿¬Ã³Ä¡
  • softening heat treatment
    ¿¬È­¿­Ã³Ä¡
  • spa treatment
    ¿Âõġ·á, ¸ñ¿åÄ¡·á
  • surgical treatment
    ¿Ü°úÄ¡·á
  • symptomatic treatment
    (¢¡expectant treatment) ±â´ëÄ¡·á
  • systemic treatment
    Àü½ÅÄ¡·á
  • treatment
    Ä¡·á, óġ
  • virtual treatment
    °¡»óÄ¡·á
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • parathyroid injection
    ºÎ°©»ó¼±ÁÖ»ç¾×(¡­ñ¼ÞÒäû).
  • paravertebral injection
    ôÃßÁÖÀ§ÁÖ»ç.
  • percutaneous ethanol injection therapy
    °æÇÇÀû ¿¡Å¸³î ÁÖÀÔ ¿ä¹ý
  • polytetrafluoroethylene injection
  • pre/post gadolinium injection
    Àü/ÈÄ °¡µ¹¸®´½ ÁÖÀÔ
  • preparatory injection
    ÁغñÁÖ»ç(¡­ñ¼ÞÒ).
  • provocative injection
    À¯¹ßÁÖ»ç(ë¯Û¡ñ¼ÞÒ).
  • rapid injection
    ±Þ¼ÓÁÖÀÔ
  • retrobulbar injection
    ´«µÚÁÖ»ç, ±¸ÈÄÁÖ»ç(¡­ñ¼ÞÒ).
  • single injection technic s. shot technic
    ÀÏȸÁÖÀϹý, ´ÜÀÏÁÖ»ç¹ý( Ó¤ìéñ¼ÞÒÛö).
  • sterile injection powder
    ¸ê±ÕÁÖ»ç¿ë ºÐ¸»(Øþжñ¼ÞÒéÄÝÏØÇ).
  • sterile injection powder
    ¸ê±ÕÁÖ»ç¿ë ºÐ¸»(Øþжñ¼ÞÒéÄÝÏØÇ)
  • subconjunctival injection
    °á¸·ÇÏÁÖ»ç (¡­ñ¼ÞÒ).
  • subcutaneous injection
    ÇÇÇÏÁÖ»ç(ÇÇÇÏ ÁÖ»ç).
  • subperiosteal injection
    °ñ¸·ÇÏ ÁÖ»ç (¡­ñ¼ÞÒ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ESI elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection
Hypo hypodermic, hypodermic injection
IDU idoxuridine; injection or intravenous drug user; iododeoxyuridine
IEC injection electrode catheter; International Electrotechnical Commission; intraepithelial carcinoma; ...
IMI immunologically measurable insulin; impending myocardial infarction; Imperial Mycological Institute ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
IM intramuscular injection
MDI multiple daily injection
PI post injection
NT 3-Nitro-L-tyrosine
IMT 3-[(123)I]iodo-alpha-methyl-L-tyrosine
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • operative treatment
    º¸Á¸Àû Ä¡·á, ¼ö¼ú ¿ä¹ý, ¼ö¼úÀû ¿ä¹ý
  • orthodontic treatment
    ±³Á¤ Ä¡·á, ±³Á¤ óġ
  • overzealous use of treatment
    °úÀ× Ä¡·á
  • phase II treatment
    Á¦2´Ü°è Ä¡·á
  • preventive treatment
    ¿¹¹æ Ä¡·á
  • previous treatment result
    °ú°Å Ä¡·á °á°ú
  • quality of treatment
    Ä¡·áÀÇ Áú
  • restorative treatment
    ¼öº¹ Ä¡·á
  • reversible treatment
    °¡¿ªÀû Ä¡·á
    ¿µ±¸ÀûÀÎ º¯È­¸¦ ÀÏÀ¸Å°Áö ¾Ê´Â ¸ðµç Ä¡·á.
  • right to refuse treatment
    Ä¡·á °ÅºÎ±Ç
  • rights to choose treatment
    Ä¡·á ¼±ÅñÇ
  • root canal treatment
    ±Ù°ü Ä¡·á
    ¹ß¼ö¿Í Á¼Àº ¶æÀÇ ±Ù°ü Ä¡·áÀÎ °¨¿° ±Ù°ü Ä¡·á
  • shock treatment
    ¼ï Ä¡·á
    Ä«¸£µð¾ÆÁ¹ °æ·Ã ¿ä¹ý, Àü±â ¼îÅ© ¿ä¹ý, Àν¶¸° ¼îÅ© ¿ä¹ý µîÀÌ ÀÖ´Ù.
  • slush treatment : ÁÂâÀÇ Ä¡·á¹ýÀ¸·Î¼­, ¼³»ó ÀÌ»êȭź¼Ò, ¾Æ¼¼Åæ, ȲÀÇ ÇÕÁ¦¸¦ »ç¿ëÇÏ´Â ¿ä¹ý.

    SMAF

    ƯÀÌ ´ë½Ä¼¼Æ÷ ¹«ÀåÈ­ ÀÎÀÚ
  • softening heat-treatment
    ¿¬È­ ¿­ ó¸®
    ±Ý¼Ó ¹× ÇÕ±Ý Àç·á´Â °¡°øÇÏ¸é ¿Ö°î ¶§¹®¿¡ ±»¾îÁø´Ù. ÀÌ °°Àº Àç·á¿¡ °¡°ø¼ºÀ» ³ôÀ̱â À§Çؼ­ ȤÀº ±âŸ ¿Ö°îÀ» ¿ÏÀüÈ÷ Á¦°ÅÇϱâ À§ÇÏ¿© ÇàÇÏ´Â ¿­ ó¸®.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
epidermal growth factor receptor protein-tyrosine kinase <enzyme> The catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of epidermal growth factor receptor.
Registry number: EC 2.7.1.-
(12 Dec 1998)
estradiol receptor tyrosine kinase <enzyme> Calcium and calmodulin dependent
Registry number: EC 2.7.1.-
Synonym: ertk
(26 Jun 1999)
tubulin-tyrosine ligase <enzyme> An enzyme that covalently links a tyrosine to the C-terminal glutamyl residue of tubulin, coupled with the hydrolysis of ATP to ADP and Pi; this is a unique posttranslational modification that may have a significant role in cytoskeletal traffic and design.
(05 Mar 2000)
tyrosine <amino acid> One of the twenty amino acids directly coded in proteins. Nonessential in humans since can be synthesised from phenylalanine.
(18 Nov 1997)
tyrosine 3-monooxygenase <enzyme> An enzyme that catalyses the conversion of l-tyrosine, tetrahydrobiopterin, and oxygen to 3,4-dihydroxy-l-phenylalanine, dihydrobiopterin, and water.
Chemical name: L-Tyrosine,tetrahydrobiopterin:oxygen oxidoreductase (3-hydroxylating)
Registry number: EC 1.14.16.2
(12 Dec 1998)
tyrosine aminotransferase <enzyme> An enzyme that catalyses the reversible reaction of l-tyrosine and alpha-ketoglutarate producing p-hydroxyphenylpyruvate and l-glutamate; this enzyme catalyses a step in l-phenylalanine and l-tyrosine catabolism; a deficiency of this enzyme is associated with tyrosinaemia II.
Synonym: tyrosine transaminase.
(05 Mar 2000)
tyrosine decarboxylase <enzyme> A pyridoxal-phosphate protein that catalyses the conversion of l-tyrosine to tyramine and carbon dioxide. The bacterial enzyme also acts on 3-hydroxytyrosine and, more slowly, on 3-hydroxyphenylalanine.
Chemical name: L-Tyrosine carboxy-lyase
Registry number: EC 4.1.1.25
(12 Dec 1998)
tyrosine-ester sulfotransferase <enzyme> Also acts on phenols and organic hydroxylamines
Registry number: EC 2.8.2.9
Synonym: arylsulfotransferase iv
(26 Jun 1999)
tyrosine hydroxylase <enzyme> Enzyme required for the synthesis of the neurotransmitters noradrenaline and dopamine.
(18 Nov 1997)
tyrosine iodinase A postulated enzyme in the thyroid catalyzing iodination of tyrosine, a reaction important in the eventual biosynthesis of thyroxine.
See: peroxidases.
(05 Mar 2000)
tyrosine kinase <enzyme> Kinases that phosphorylate protein tyrosine residues. These kinases play major roles in mitogenic signalling and can be divided into two subfamilies: receptor tyrosine kinases, that have an extracellular ligand binding domain, a single transmembrane domain and an intracellular tyrosine kinase domain and nonreceptor tyrosine kinases, which are soluble, cytoplasmic kinases.
(18 Nov 1997)
tyrosine N-monooxygenase <enzyme> Catalyses the n-hydroxylation of l-tyrosine to n-hydroxytyrosine
Registry number: EC 1.14.13.41
Synonym: tyrosine n-hydroxylase, haemthiolate enzyme, cytochrome p450(tyr), cyp79 protein
(26 Jun 1999)
tyrosine phenol-lyase <enzyme> An enzyme that catalyses the cleavage of tyrosine to phenol, pyruvate, and ammonia. It is a pyridoxal phosphate protein. The enzyme also forms pyruvate from d-tyrosine, l-cysteine, s-methyl-l-cysteine, l-serine, and d-serine, although at a slower rate.
Chemical name: L-Tyrosine phenol-lyase (deaminating)
Registry number: EC 4.1.99.2
(12 Dec 1998)
tyrosine phosphorylation <enzyme> Kinases that phosphorylate protein tyrosine residues. These kinases play major roles in mitogenic signalling and can be divided into two subfamilies: receptor tyrosine kinases, that have an extracellular ligand binding domain, a single transmembrane domain and an intracellular tyrosine kinase domain and nonreceptor tyrosine kinases, which are soluble, cytoplasmic kinases.
(18 Nov 1997)
tyrosine-repressible transaminase <enzyme> From E coli; catalyses the amination of 2-ketoisocaproate to leucine; encoded by tyrb; a functional leuabcd operon is required for leucine synthesis by this enzyme
Registry number: EC 2.6.1.-
Synonym: transaminase d, tyrosine-2-ketoisocaproate aminotransferase
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á